Abbott Laboratories (ABT)
$54.08
-0.33 (-0.61%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $54.41 |
| Daily Range | $53.29 - $54.34 |
| 52-Week Range | $41.27 - $57.39 |
| Market Cap | $83.65B |
| P/E Ratio | 14.76 |
| Dividend (Yield) | 1.60 (2.90%) |
| Volume | 2,889,377 |
| Average Daily Volume | 6,738,000 |
ABT
VS S&P 500 (SPY)
How do you think ABT will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ABT Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ABT News and Commentary
- A Mostly Meaningless FDA Approval – The Motley Fool
- A Big Upgrade for Amylin Pharmaceuticals – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- 7 All-Star Stocks to Make Your Portfolio Shine – The Motley Fool
- 52-Week Highs! What's Going On? – The Motley Fool
- Prescriptions For Merck Cholesterol Drugs Dropped Last Week – SmartMoney
- The Side Effect of Developing Obesity Drugs – The Motley Fool
- How I'm Grabbing 20% Dividend Yields – The Motley Fool
- UPDATE: FDA Reviewing Safety Of Weight-Loss Drug Meridia – SmartMoney
- UPDATE 2-US FDA reviewing Abbott diet drug risks – Reuters
- FDA Reviewing Safety Of Weight-Loss Drug Meridia – SmartMoney
- UPDATE 1-US FDA reviewing Abbott diet drug risks – Reuters
- 5-Star Stocks Worth a Look – The Motley Fool
- Abbott Hesitates To Promote Niaspan Study Due To FDA Rules – SmartMoney
- Why You Can't Afford to Miss These Stocks – The Motley Fool
- Drug Lowers Cholesterol; Stock Follows – The Motley Fool
- UPDATE: Study Questions Utility Of Merck Cholesterol Drugs – SmartMoney
- Another Study Questions Utility Of Merck Cholesterol Drugs – SmartMoney
- UPDATE 1-FDA warns Abbott over diagnostics manufacturing – Reuters
- FDA Warns Abbott Over Manufacturing Violations At Plant – SmartMoney
RSS Headlines
Fool UK
